Prevalence of Fractures Among Men with Stage IV Prostate Cancer

Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that do not have distant metastasis.  This increased risk, or actually the increase of fractures has significant clinical consequences, such as [...]

On the Horizon – Targeting Bones in the Treatment of Advanced Prostate Cancer

Osteoblasts and osteoclasts are the process that the body uses to breakdown old bone and then to rebuild it with new bone. c-Met is a tyrosine kinase expressed by osteoblasts and osteoclasts, and overexpressed by prostate cancer cells. This over expression leads to the eventual development of bone metastases. The experimental treatment known as Cabozantinib [...]

On the Horizon – Denosumab, An alternative To Zometa To Protect Bones While Treating Advanced Prostate Cancer

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]

ADT Increases Risk Factors for Diabetes, Fractures and Cardiovascular Mortality

Not a very big surprise but androgen-deprivation therapy (ADT) substantially increases the risk for cardiovascular and bone-related problems, as well as for diabetes, according to a review of the medical literature published online April 27 in the journal Cancer. At the University of Texas Health Science Center in Houston, Lockwood G. Taylor wrote a review [...]